? BIOMEDICAL RESEARCH SUPPORT SHARED RESOURCE New Cancer Center Support Grant Shared Resource The Biomedical Research Support Shared Resource (BRSSR) enables Cancer Center members to perform human subject research in the context of partnerships between Wistar investigators and clinical care providers. Introduced as a developmental core at the 2013 Cancer Center Support Grant (CCSG) renewal, the BRSSR has been launched as a full-service Cancer Center Shared Resource during the last CCSG budget cycle. By providing a centralized resource for human subject-based research at Wistar, the BRSSR makes available to Cancer Center investigators a comprehensive menu of services to (i) coordinate the procurement of human subject-derived biospecimens from clinical partners, volunteers (phlebotomy service) or commercial partners; (ii) provide expertise in fulfilling research compliance with ethical and regulatory mandates; (iii) assist investigators to ensure that biospecimen and data collection is conducted in compliance with Good Clinical Practice (GCP), regulatory mandates (e.g. 21 CFR Part 11, HIPAA etc.) and contractual obligations; (iv) provide access to tissue processing and advanced histotechnology techniques for specimens analysis; and (v) provide low-cost, customized solutions for centralized data storage and management that ensure the consistency, completeness and quality of the data received from clinical providers. Our collaborative partnership with the Helen F. Graham Cancer Center (HFGCC) at Christiana Care Health System (CCHS), a member Institution of the National Community Cancer Center Program (NCCCP), provides Wistar Cancer Center members with access to fresh biospecimens, including fine-needle aspirate, biopsies, surgical resections, and biological fluids from cancer patients, instrumental to fulfill the mission of the Cancer Center in translational and patient-focused cancer research. Substantial institutional investments have been made to develop and validate an electronic data management platform, CDETweb Toolbox, to manage human subject data in the BRSSR. As fully deployed, the CDETweb platform is customizable to meet specific data collection and sample tracking needs, supporting multiple data entry modes (e.g. keying and direct uploads), randomization, asymmetrical visit schedules, screening and entry criteria gatekeeping, and other custom-defined requirements. BRSSR services also support a phlebotomy service (protocol management, donor management, testing, etc.) and access to tissue microarray services (array design and customization, ordering and tracking). As a result, the BRSSR provides a robust infrastructure to support mechanistic, patient-oriented research by managing all aspects of procurement of human subject-derived biospecimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-52
Application #
10145609
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
52
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445
Duperret, Elizabeth K; Liu, Shujing; Paik, Megan et al. (2018) A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clin Cancer Res 24:6015-6027

Showing the most recent 10 out of 741 publications